Back to News
Oct 6, 2025 4:20 PM

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies, a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NASDAQ:AZN) to accelerate the discovery of novel therapeutic targets in immunology.

Under the agreement, Algen will leverage its AlgenBrain platform to drive preclinical drug discovery.

AstraZeneca receives exclusive rights to develop and commercialize therapies against a set of targets identified and selected through the partnership.

Algen will receive an upfront payment from AstraZeneca and additional payments upon achieving specific development, regulatory, and commercial milestones, with a potential total deal value of $555 million.

Also Read: Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

AlgenBrain models disease progression by capturing billions of dynamic RNA changes in human, disease-relevant cell types, and ...